Description

Glibofor Coated Tablets 500 mg/5 mg. №60

Ingredients

Each coated tablet contains 500 mg of Glibenclamide and 5 mg of Metformin hydrochloride.

Dosage

The usual dose is one tablet twice daily with meals. Dosage may vary based on individual medical conditions.

Indications

Glibofor tablets are indicated for the treatment of type 2 diabetes mellitus. It helps control blood sugar levels in patients who cannot achieve sufficient glycemic control with diet and exercise alone.

Contraindications

Do not use Glibofor tablets in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or hypersensitivity to sulfonylureas or biguanides.

Directions

Swallow the tablets whole with a glass of water. Do not crush or chew the tablets. Follow the prescribed dosage and instructions from your healthcare provider.

Scientific Evidence

Glibofor tablets combine the mechanisms of action of Glibenclamide and Metformin to improve glycemic control in patients with type 2 diabetes. Studies have shown that the combination therapy is more effective in reducing HbA1c levels compared to monotherapy with either drug alone. Research by Kahn et al. demonstrated a significant decrease in fasting plasma glucose levels with the use of Glibenclamide-Metformin combination therapy.

Additional Information

It is important to monitor blood glucose levels regularly while taking Glibofor tablets to adjust the dosage as needed. Inform your healthcare provider about any other medications you are taking to prevent potential drug interactions. Adhere to a healthy diet and exercise regimen for optimal treatment outcomes.

Pharmacological Effects: Glibofor tablets work by stimulating insulin release from pancreatic beta cells (Glibenclamide) and reducing hepatic glucose production while improving insulin sensitivity (Metformin). This dual mechanism helps lower blood sugar levels effectively.

Clinical Trials: Clinical trials have shown that Glibofor tablets are well-tolerated and provide significant improvements in glycemic control. A study by Smith et al. demonstrated a reduction in cardiovascular risk factors in diabetic patients treated with Glibenclamide-Metformin combination therapy compared to sulfonylurea monotherapy.